key: cord-0325596-0xh1rv9d authors: Chen, Jade; San, Su Su Soe; Kung, Amelia; Tomasek, Michael; Liu, Dakai; Rodgers, William; Gau, Vincent title: Direct-from-specimen microbial growth inhibition spectrums under antibiotic exposure and comparison to conventional antimicrobial susceptibility testing date: 2021-02-12 journal: bioRxiv DOI: 10.1101/2021.02.12.430910 sha: a81c0e8cc570897259f06d32f4280117367db70e doc_id: 325596 cord_uid: 0xh1rv9d Increasing global travel and changes in the environment may increase the frequency of contact with a natural host carrying an infection, and therefore increase our chances of encountering microorganisms previously unknown to humans. During an emergency (man-made, natural disaster, or pandemic), the etiology of infection might be unknown at the time of patient treatment. The existing local or global Antimicrobial Stewardship Programs might not be fully prepared for emerging/re-emerging infectious disease outbreaks, especially if they are caused by an unknown organism, engineered bioterrorist attack, or rapidly evolving superbug. We demonstrate an antimicrobial efficacy profiling method that can be performed in hours directly from clinical urine specimens. The antimicrobial potency is determined by the microbial growth inhibition and compared to conventional antimicrobial susceptibility testing (AST) results. The oligonucleotide probe pairs on the sensor were designed to target gram-negative bacteria, specifically Enterobacterales and Pseudomonas aeruginosa. A total of 10 remnant clinical specimens from the CLIA labs of New York-Presbyterian Queens were tested, resulting in 100% categorical agreement with reference AST methods (Vitek and broth microdilution method). The combined categorical susceptibility reporting of 12 contrived urine specimens was 100% for ciprofloxacin, gentamicin, and meropenem over a range of microbial loads from 105 to 108 CFU/mL. 7 144 145 Antibiotic exposure stripwell inoculation and molecular quantification 146 One hundred microliters of reconstituted specimen pellets (1x and 0.1x) were inoculated into each well of an 147 AST stripwell. All stripwells were incubated at 35°C for the exposure time indicated in each study. Thirty-six 148 microliters of 1M NaOH were added to each well to lyse target gram-negative pathogens after antibiotic exposure 149 with a 3-minute incubation at room temperature. Twenty-four microliters of 1M HCl were then added to each well 150 to neutralize the pH of the lysed sample, or lysate, and prevent the degradation of free RNA. Ten microliters of 151 the lysate from each well were pipetted to its corresponding sensors on two electrochemical sensor chips (a total 152 of 4 sensors per well). No sample was delivered to the negative control sensors. All chips were incubated for 30 153 minutes at 43°C, and the RNA content was quantified for microbial growth response as described above. 154 155 Clinical feasibility validation with blind clinical specimens 156 The clinical specimens for the blind testing study were remnant specimens collected at NYPQ under the current 157 IRB. Incoming urine specimens for urine culture as part of routine care with confirmed positives for either 158 Enterobacterales or Pseudomonas aeruginosa were shipped overnight to GeneFluidics for testing. De-159 identification and data analysis were performed by administrative staff. Species belonging to the 160 Enterobacterales family such as Escherichia coli, Klebsiella spp., and Enterobacter spp. are the major cause of 161 urinary tract infections, blood-stream infections, and healthcare-associated pneumonia [49] [50] . The 162 Enterobacterales family and Pseudomonas aeruginosa were selected due to their increasing resistance to 163 commonly used antimicrobial agents [51] . 164 165 Statistical analysis 166 Signals generated from each sensor from enzymatic reaction with TMB substrate were analyzed with three 167 different algorithms for comparison. Before reporting GC ratio, the algorithm first assessed the signal level from 168 the negative and growth controls from each sensor chip. If either control was out of the acceptable range (i.e., 169 greater than 50 nA for the negative control, less than 50 nA for the growth control), the algorithm reported "NC 223 μg/mL (two 2-fold dilutions above the Enterobacterales resistant breakpoint). As shown in Fig 2A, all microbial 224 response curves of resistant K. pneumoniae CDC 79 (no-fill pattern) were overlapping at the GC ratios at around 225 1.0 (see S2 Table for GIC reporting from all three algorithms) , indicating no inhibited growth no matter how long 226 the exposure time was. However, there was a clear trend of inhibited growth with lower GC ratios with the 227 susceptible E. coli CDC 69 (gradient pattern), indicating more significant inhibited growth while increasing the 228 exposure time or ciprofloxacin concentration. The reported GIC value from the Maximum Inhibition algorithm 229 (see Algorithm section for details) is listed to the right of each response curve. We then repeated the same 230 protocols with the contrived urine samples to evaluate the impact of the urine matrix components in Fig 2B. The 231 bolded GIC value (S strain in MH 30 min, S strain in urine 30 min, S strain in urine 60 min) represents incorrect 232 categorical susceptibility reporting, which occurs when the exposure time is insufficient. The microbial growth 233 inhibition curves from contrived urine samples in Fig 2B exhibit identical characteristics as those in culture media 234 in Fig 2A. This suggests the supernatant removal step is efficient enough to remove urine matrix, but not too 235 harsh to put the pathogen into the stationary phase. 236 237 Since a shorter antimicrobial exposure time might result in errors in categorical susceptibility reporting due to 238 insignificant growth inhibition of susceptible strains compared to resistant ones as shown in Figs 2A and 2B 239 without a more sophisticated algorithm, we suspected the similar insignificant growth inhibition separation could 240 occur if the microbial load is much higher than the standard inoculum density of 5x10 5 CFU/mL. We needed to 241 adjust the antibiotic exposure time and the matrix interference reduction procedures for each specimen types for 242 the maximum differential antimicrobial efficacy profiling between susceptible and resistant strains over a 243 physiological range of microbial loads. Contrived urine samples were used at three different microbial loads 244 against a different class of antibiotic. To explore biological, chemical and molecular analytical limitations, shorter 245 antibiotic exposure times were used for urine samples in Fig 2C to assess the separation of responses curves 246 from both resistant and susceptible strains. Antimicrobial efficacy profiling tests directly from urine contrived 247 samples were evaluated. Based on the trend of GC ratio changing along the increasing meropenem 248 concentrations (0.5 to 32 µg/mL), the GIC would be reported as "susceptible" (≤ S-breakpoint of 1 µg/mL for 249 meropenem) for E. coli CDC 77 (MIC: ≤ 0.12 μg/mL) and "resistant" (≥ R-breakpoint of 4 μg/mL for meropenem) 252 To establish a higher correlation between the MIC and GIC values it would be necessary to incorporate the 253 impact of inoculum effect on the GIC reporting, which is not within the scope of this initial study. With higher 254 contrived concentrations, we expect the inflection point would be higher due to the higher bug-to-drug ratio. Even 255 for susceptible strains, microbial growth can be observed at low antibiotic exposure concentrations at or below 256 the susceptible breakpoint if the microbial load is higher than the typical inoculation concentration at 5x10 5 257 CFU/mL. Fig 5D. Similar microbial responses were observed in the rapid ciprofloxacin 332 exposure study with the same E. coli CDC 69 strain in Fig 2B; the GIC value jumped from 0.0625 μg/mL (90-min 333 exposure) to 1 μg/mL (30-min and 60-min exposure). The GC signal levels as shown in S5 Table were saturated 334 at 10,000 nA for 10 7 and 10 8 CFU/mL, so the reported GIC value is expected to be higher than the MIC values 335 due to the inoculum effect. Table 1 of the dual-kinetic-curve response in Fig 343 5 using the Maximum Inhibition algorithm is the maximum GC reduction in both microbiological response plots, 344 so the combined GIC corresponds to the greatest change in the slope of both response curves. Table 1 is the 345 summary of the individual and combined GIC reporting from all contrived concentrations in Fig 5. Since the 346 combined categorical susceptibility is determined by the largest GC ratio change in an extended antimicrobial 347 spectrum (1x and 0.1x combined), it represents the most significant growth inhibition caused by the antimicrobial 348 exposure throughout the entire spectrum. Even though there was one categorical susceptibility reporting error 349 in the 1x curve in Fig 5D, all combined categorical susceptibility reports were correct for all conditions. The 350 purpose of the combined GIC reporting from a dual-kinetic-curve response is to only report the maximum growth 351 inhibition and discard GIC reporting errors due to very high or very low microbial loads. . The categorical susceptibility reporting of "susceptible" was correct over a range of 10 4 364 CFU/mL (0.1x of 10 5 CFU/mL) to 10 6 CFU/mL (0.1x of 10 7 CFU/mL). A reporting of 8 μg/mL GIC from 10 7 365 CFU/mL (1x of 10 7 CFU/mL and 0.1x of 10 8 CFU/mL) is one dilution higher than the MIC of 4 μg/mL, and it is 366 acceptable for essential agreement but a minor error for categorical agreement. The GIC reporting of 16 μg/mL 367 from 10 8 CFU/mL was a major error. The GC signal levels as shown in S6 Table were saturated Table 2 is the summary of the individual and combined GIC reporting from all contrived concentrations in Fig 6. 377 The MIC value of E. coli CDC 451 is 8 μg/mL and therefore intermediate, but our microdilution indicated the MIC 378 was 4 μg/mL and would be classified categorically as susceptible. The combined response GIC for Fig 6C and 379 6D would be 8 μg/mL to report the maximum growth inhibition, but the combined GIC was adjusted due to signal 380 level saturated at the growth control (GC) and low antibiotic concentrations (1 and 2 μg/mL in 1x response curve 381 in Fig 6C, 1 -8 μg/mL in 1x response curve and 1-4 μg/mL in 0.1x response curve in Fig 6D) . The electrochemical 382 current reading is set to saturate at 10,000 nA to maximize the resolution at lower current readings around the 383 limit of detection. So, the reading would be saturated if the microbial load were too high (>10 8 CFU/mL). The 384 reported GIC was adjusted one dilution down for every antibiotic concentration reported saturated at 10,000 nA. 385 So the GIC reporting of combined responses from Figs 6C and 6D was adjusted from 8 μg/mL to 4 μg/mL. There 386 were three categorical susceptibility reporting errors in Figs 6C and 6D compared to the microdilution, and all 387 combined categorical susceptibility reporting were correct for all conditions. 388 389 390 GIC reporting of original sample (1X), dilution (0.1X), and combined dual-curve response of a gentamicin 391 susceptible strain with an MIC of 4 μg/mL. 392 393 Similar results were observed for the same study with meropenem in Fig 7. The reported GIC transitioned from 394 ≤0.5 μg/mL (susceptible), 4 μg/mL (susceptible), to 32 μg/mL (resistant). The categorical susceptibility reporting 395 of "resistant" was correct over a range of10 5 CFU/mL to 10 8 CFU/mL. A reporting of ≤0.5μg/mL GIC from 10 4 396 CFU/mL (0.1x of 10 5 CFU/mL) was a very major error for categorical agreement, but the GC signal level as 397 shown in S7 Table was 39 nA, which is considered "no growth." No GIC value would be reported in the case of 398 GC failure (<50 nA). 399 400 Table 3 is the summary of the individual and combined GIC reporting in Fig 7. The MIC value of K. pneumoniae 401 CDC 79 is 8 μg/mL as listed in CDC AR bank database, but our microdilution indicated the MIC was 4 μg/mL. 402 The combined response GIC for Figs 7A and 7D would be 0.5 and 32 μg/mL, respectively, to report the maximum 403 growth inhibition, but the combined GIC was adjusted due to growth control failure (39 nA for 0.1x of 10 5 CFU/mL) 404 and the signal level saturated at the growth control (GC) and five low antibiotic concentrations (0.5 to 16 μg/mL 405 in 1x response curve in Fig 7D) . Originally, there was only one categorical susceptibility reporting error in Fig 7A, 406 but it would not be reported due to GC fail. All combined categorical susceptibility reports were correct for all 407 conditions. 408 409 After the initial validation of the presented microbial growth inhibition response curves to antibiotic exposure 419 conditions with CDC clinical strains, we conducted a pilot feasibility study on blinded urine specimens from 420 NYPQ. De-identified clinical remnant specimens were shipped overnight to GeneFluidics for testing as 421 described above, and the summary of combined categorical susceptibility is detailed in Table 4 . Sample #7 422 was positive for P. aeruginosa but when tested with the assay produced a GC fail. Subculture of NYPQ sample 423 #7 on Chromagar plate indicated two separate strains, so the original specimen might have been a 424 polymicrobial infection or there was contamination during sample collection or testing. The species-specific 425 susceptibility reporting would require the pathogen identification (ID) sensor chip with complementary 426 oligonucleotide probes against each target pathogen, which is outside the scope of this study. All other nine 427 specimens were reported correctly to match the categorical susceptibility verified by NYPQ. All individual and 428 combined GIC reports are listed in S8 The inhibited growth cutoff method reported the highest antibiotic concentration with a GC 175 ratio lower than a predetermined cutoff value, so the GIC was determined solely based on the signal level from 176 each antibiotic exposure condition normalized to the one from the growth control. Initial assessment used both 177 0.4 and 0.5 as cutoff values with on-scale strains to determine the final cutoff value. The maximum inhibition 178 method reported the GIC as the highest antibiotic concentration after the maximum GC reduction in a 179 microbiological response plot against a series of 2-fold dilutions of the antibiotic of interest Any direct-from-specimen antimicrobial efficacy profiles found to be misclassified (i.e., GIC higher than the for GIC to MIC comparison only, the discrepant GIC/MIC values (i.e., GIC 2-fold above or below the 193 MIC value from the clinical microbiology lab) were retested and compared to the microdilution reference method Since the direct-199 from-specimen microbial growth inhibition test starts with a specimen with unknown pathogen concentration from 200 0 to > 10 8 CFU/mL in different specimen types, the correlation between the limit of detection (LOD) of the current 201 molecular analysis platform with the assay turnaround time (TAT) was established in Fig 1 in order to determine 202 the minimum assay time needed for quantification of RNA transcription at different levels of pathogen 203 concentrations. As shown in Fig 1C, the TAT and dynamic range of ID can be configured to be from 16 minutes 204 to 36 minutes by adjusting the analyte incubation time for higher target LODs. Target pathogen enrichment and 205 matrix component removal can be carried out by centrifugation to achieve lower target LODs with TAT of 42 206 minutes to 110 minutes. For low-abundance pathogens and early infection diagnostics Fig 1. Calibration curves of configurable ID protocols with various TAT and LODs We first focus on the feasibility of assessing microbial growth inhibition without the potential interference of matrix 215 effects by using contrived samples in culture media Since the goal of the pilot study was to investigate the potential 219 interference in urine, the spiked concentration was set to 10 7 CFU/mL. Three antibiotic exposure times (30, 60, 220 and 90 minutes) were tested as primary parameters for optimization. Microbial growth inhibition was plotted with 221 the signal ratios normalized to the one from the growth control, GC ratio Both intermediate strains reported a GIC value two-fold lower 305 than the MIC values from the reference methods. The essential agreement based on MIC/GIC values are 306 acceptable, but both intermediate strains had minor errors according to the CLSI M100 and FDA Class II Special 307 Controls Guidance for AST systems Direct-from-urine antimicrobial efficacy profiling of pathogens with a range of on-scale MIC values All urine specimens contrived at 10 6 CFU/mL. (A) Ciprofloxacin responses. (B) Gentamicin responses. Bolded 311 GIC values indicate incorrect categorical susceptibility microbial load is too high (Fig 315 2C), or the MIC is on intermediate or resistant breakpoints (Figs 3C-D and 4A-B). Besides extending the 316 antimicrobial exposure time, especially for time-dependent antibiotics such as meropenem, we explored the 317 feasibility of a dual-kinetic response approach to cover a broader range of microbiological responses by 318 inoculating two sets of seven antimicrobial concentrations in two antibiotic stripwells with clinical specimens at 319 the original concentration (1x) and the 10-fold dilution (0.1x). Additionally, to ensure that the current GIC reporting 320 algorithm is correlated with the microbial susceptibility and MIC values throughout the physiological range, a set 321 of microbial loads in urine (10 5 to 10 8 CFU/mL) were tested in Fig 5, and the GIC was calculated from the dual 322 kinetic (1x and 0.1x) curves. The inflection point shifted toward higher antibiotic concentrations with higher 323 microbial loads, but the GICs were the same without the inoculum effect adjustment (see S5 Table for GIC 324 reporting from all three algorithms) -fold), the 327 symmetrical characteristics result in overlapping GC ratio curves. Figs 5A-D show the transition of GIC reporting 328 from ≤0.0625 μg/mL (susceptible), 0.125 μg/mL (susceptible), to 1 μg/mL (resistant). The categorical 329 susceptibility reporting of The GIC value jumped from 0.125 μg/mL (0.1x of 10 8 CFU/mL) to 1 μg/mL (1x 446 or susceptible strains were selected for testing [56]. For slow-growing pathogens, a longer antibiotic-exposure 447 incubation would be required. Khazaei et. al. demonstrated that quantifying changes in RNA signatures instead 448 of DNA replication resulted in significant shifts (>4-fold change) in transcription levels within 5 min C:T ratio) dispersion from highly 450 susceptible strains with MICs at least seven 2-fold dilutions below the resistant break point. The C:T ratio can /mL, while 452 the C:T ratio separation between the resistant and susceptible populations is only The first challenge is that most growth-based susceptibility testing 457 requires a standardized inoculum where a known concentration of organism is used for AST. In routine testing, 458 the organism concentration is fixed, and it may be significantly higher than what is encountered in a clinical 459 specimen which may be used for direct inoculation. An exception may be the urine culture, where patients with 460 real infections commonly have more than 10 5 CFU/ml. Mezger et al. published a proof-of-concept study in which 461 urine was used as an inoculum for rapid AST [59]. This method employed a brief incubation period (∼120 min) 462 followed by quantitative PCR designed to quantify growth. Pilot experiments showed that the assay was able to 463 accurately determine E. coli susceptibility to ciprofloxacin and trimethoprim within 3.5 h, however the 464 susceptibility profiling algorithm was not correlated to CLSI M100 categorical reporting. This challenge is 465 addressed by assessing susceptibility response dynamic trends at three different bug/drug ratios by inoculating 466 the raw specimens in two dilutions as detailed above. The second challenge is to provide susceptibility profiling 467 equivalent to AST reported by a clinical microbiology lab with >95% categorical agreement. The third challenge 468 is the need to ensure pathogens are isolated from clinical samples to allow for retesting Despite being recognized as the standard quantitative index of antimicrobial potency, the MIC is subject to 473 several limitations. It is determined only at the end-point between 16 and 24 hours Several static and dynamic in vitro and in vivo infection model 477 studies have been demonstrated for analysis and interpretation of in vitro efficacy results of antimicrobial drugs 478 as an alternative to MIC reporting An ideal growth inhibition spectrum can fit concentration-responses in sigmoidal curves that are symmetrical 482 about its inflection point and flattened on both ends with statistical fluctuations as shown in Figs 5-7. The left 483 plateau represents insignificant grow inhibition under antibiotic exposures below the MIC, and the right plateau 484 represents significant grow inhibition above the MIC. The inflection point indicates the concentration at which 485 antimicrobial potency lies midway between non-inhibited growth (left plateau) and total inhibited growth Based on this hypothesis, we developed a direct-from-specimen microbial 493 growth inhibition test with two dilutions from unprocessed clinical specimens (1x and 0.1x) as inoculums for two 494 sets of antibiotic exposure stripwells with one GC and seven antibiotic concentrations each to generate a 495 microbial growth inhibition spectrum. As the drug concentration increases, the probability that drug molecules 496 reach a lethal concentration increases as a function modeled by a smooth sigmoidal curve ) quality control to eliminate the data set if 500 there is no growth due to microbial load below limit of detection (LoD). A tentative algorithm has been developed 501 to identify the antibiotic concentration at the inflection point adjusted by the microbial load from the signal level 502 from GC wells, and the reported GICs were compared to MIC from reference methods or FDA cleared systems The Slow March toward Rapid Phenotypic Antimicrobial Susceptibility Testing: Are We There Yet? Antibiotic treatment for COVID-19 complications could fuel resistant bacteria Clinical Characteristics of Coronavirus Disease 2019 in China Clinical Characteristics of 34 Children with Coronavirus Disease-2019 in the West of China: a Multiple-center Case Series WHO warns overuse of antibiotics for Covid-19 will cause more deaths. The Guardian Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Secondary Bacterial Infections Associated with Influenza Pandemics Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness Rapid antimicrobial susceptibility testing by sensitive detection of precursor rRNA using a novel electrochemical biosensing platform Target-specific capture enhances sensitivity of electrochemical detection of bacterial pathogens Highly sensitive disposable nucleic acid biosensors for direct bioelectronic detection in raw biological samples Ternary monolayers as DNA recognition interfaces for direct and sensitive electrochemical detection in untreated clinical samples Redox cycling amplified electrochemical detection of DNA hybridization: application to pathogen E. coli bacterial RNA Ternary Surface Monolayers for Ultrasensitive Amperometric Detection of Nucleic-Acid Hybridization without Signal Amplification A Microfluidic Cartridge System for Multiplexed Clinical Analysis Potentiometric detection of DNA hybridization using enzyme-induced metallization and a silver ion selective electrode An unsteady microfluidic T-form mixer perturbed by hydrodynamic pressure Electrochemical molecular analysis without nucleic acid amplification Rapid, species-specific detection of uropathogen 16S rDNA and rRNA at ambient temperature by dot-blot hybridization and an electrochemical sensor array An AC electrokinetics facilitated biosensor cassette for rapid pathogen identification Biosensor diagnosis of urinary tract infections: a path to better treatment? Matrix-insensitive protein assays push the limits of biosensors in medicine Hybrid electrokinetic manipulation in high-conductivity media System Integration -A Major Step toward Lab on a Chip Antimicrobial susceptibility testing using high surface-to-volume ratio microchannels Electrochemical immunosensor detection of urinary lactoferrin in clinical samples for urinary tract infection diagnosis Electrothermal Fluid Manipulation of High-Conductivity Samples for Laboratory Automation Applications Matrix Effects-A Challenge Toward Automation of Molecular Analysis A Microfluidic Cartridge System for Multiplexed Clinical Analysis Active manipulation of quantum dots using AC electrokinetics A point-of-care micro-laboratory for direct pathogen identification in body fluids A Universal Electrode Approach for Molecular Diagnostics Single cell antimicrobial susceptibility testing by confined microchannels and electrokinetic loading An AC electrokinetics facilitated biosensor cassette for rapid pathogen identification Electrokinetic focusing and separation of mammalian cells in conductive biological fluids In situ electrokinetic enhancement for selfassembled-monolayer-based electrochemical biosensing A Biosensor Platform for Rapid Antimicrobial Susceptibility Testing Directly from Clinical Samples Statistical Metamodeling for Revealing Synergistic Antimicrobial Interactions Hybrid Electrokinetics for Separation, Mixing, and Concentration of Colloidal Particles A MEMS based amperometric detector for E. coli bacteria using self-assembled monolayers Electrochemical molecular analysis without nucleic acipd amplification Use of electrochemical DNA biosensors for rapid molecular identification of uropathogens in clinical urine specimens Development of an advanced electrochemical DNA biosensor for bacterial pathogen detection A microfluidic cartridge system for multiplexed clinical analysis Evaluation of an automated rRNA quantitation system for rapid AST in clinical lab diagnostics Annual Meeting Abstracts RNA markers enable phenotypic test of antibiotic susceptibility in Neisseria gonorrhoeae after 10 minutes of ciprofloxacin exposure A classification based framework for quantitative description of large-scale microarray data Electrochemical Biosensors -Sensor Principles and Architectures. Sensors (Basel) Resistance in gram-negative bacteria: enterobacteriaceae Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It Antibiotic Resistance, Part 2: Gram-negative Pathogens CLSI supplement M100. Performance Standards for Antimicrobial Susceptibility Testing Guidance for industry and FDA. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems. Silver Spring, MD: Center for Devices and Radiological Health, U.S. Food and Drug Administration Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors Comparative in-vitro properties of the quinolones Rapid pathogen-specific phenotypic antibiotic susceptibility testing using digital LAMP quantification in clinical samples RNA markers enable phenotypic test of antibiotic susceptibility in Neisseria gonorrhoeae after 10 minutes of ciprofloxacin exposure The obligate human pathogen, Neisseria gonorrhoeae, is polyploid A general method for rapid determination of antibiotic susceptibility and species in bacterial infections Determination of minimum inhibitory concentrations Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling Choosing an antibiotic on the basis of pharmacodynamics In vitro pharmacodynamic models to determine the effect of antibacterial drugs Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model Pharmacokineticpharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillinresistant Staphylococcus aureus Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration Effects of Inoculum Size and Incubation Time on Broth Microdilution Susceptibility Testing of Lactic Acid Bacteria Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method Bacterial resistance to antimicrobial agents used in fish farming: a critical evaluation of method and meaning Clinical isolate counts with strain # and antimicrobial tested (MIC) GIC reporting values for Fig 2A. Ciprofloxacin GIC reporting with three algorithms for E. coli CDC 507 69 with a MIC of ≤ 0.0625 μg/mL and K. pneumoniae CDC 79 with an MIC of >8 μg/mL for Fig 2A Ciprofloxacin GIC reporting with three algorithms for E. coli CDC 509 69 with a MIC of ≤ 0.0625 μg/mL and K. pneumoniae CDC 79 with a MIC of >8 μg/mL for Fig 2B S2C Table. GIC reporting values for Fig 2C. Meropenem GIC reporting with three algorithms for E. coli CDC GIC reporting values for Fig 5. Ciprofloxacin GIC reporting with three algorithms for E GIC reporting of NYPQ blinded clinical specimens